Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Parity, oral contraceptives, and the risk of ovarian cancer among carriers and noncarriers of a BRCA1 or BRCA2 mutation.

The New England journal of medicine - 26 Jul 2001

Modan B, Hartge P, Hirsh-Yechezkel G, Chetrit A, Lubin F, Beller U, Ben-Baruch G, Fishman A, Menczer J, Struewing J P, Tucker M A, Wacholder S

Abstract excerpt

BACKGROUND: Multiparity and the use of oral contraceptives reduce the risk of ovarian cancer, but their effects on this risk in women with a BRCA1 or BRCA2 mutation are unclear. METHODS: We conducted a population-based case-control study of ovarian cancer among Jewish women in Israel. Women were tested for the two founder mutations in BRCA1 and the one founder mutation in BRCA2 that are known to be common among...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to BRCA2 Protein
Share to Contraceptives, Oral

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genes, BRCA1

Share to Germ-Line Mutation

Share to Logistic Models

Share to Ovarian Neoplasms

Share to Parity

Source

Identifiers

PMID: 11474660
DOI: 10.1056/NEJM200107263450401

Genes

BRCA1
BRCA2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Parity, oral contraceptives, and the risk of ovarian cancer among carriers and noncarriers of a BRCA1 or BRCA2 mutation.PMID 11474660Read ↗

Reproductive factors and ovarian cancer risk in Jewish BRCA1 and BRCA2 mutation carriers (United States).Semantic proximity Read ↗

Gynecologic surgeries and risk of ovarian cancer in women with BRCA1 and BRCA2 Ashkenazi founder mutations: an Israeli population-based case-control study.Semantic proximity Read ↗

Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.Semantic proximity Read ↗

Fertility treatments and invasive epithelial ovarian cancer risk in Jewish Israeli BRCA1 or BRCA2 mutation carriers.Semantic proximity Read ↗

Fertility treatments and breast cancer risk in Jewish Israeli BRCA mutation carriers.Semantic proximity Read ↗

Breast and ovarian cancer risk and risk reduction in Jewish BRCA1/2 mutation carriers.Semantic proximity Read ↗

Cancer risk in Jewish BRCA1 and BRCA2 mutation carriers: effects of oral contraceptive use and parental origin of mutation.Semantic proximity Read ↗

Breast cancer incidence in BRCA mutation carriers with ovarian cancer: A longitudal observational study.Semantic proximity Read ↗

Hereditary breast and ovarian cancer due to mutations in BRCA1 and BRCA2.Semantic proximity Read ↗

BRCA1 and BRCA2 mutation analysis of 208 Ashkenazi Jewish women with ovarian cancer.Semantic proximity Read ↗

Risk-reducing salpingo-oophorectomy and breast cancer incidence among Jewish BRCA1/BRCA2-mutation carriers-an Israeli matched-pair study.Semantic proximity Read ↗

Hormone replacement therapy is more prevalent among Jewish BRCA1/2 mutation carriers.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.